Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 12

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1
Chunk 12
---
, a substantial number of cancer patients’ tumors are non-responsive or become refractory to immune checkpoint inhibitors. We believe that a PD-L1 Boltbody ISAC has the potential to overcome the limitations of current anti-PD-L1 therapies. 

Our Corporate History and Team 

Our company was founded in 2015 to develop and commercialize pioneering work from the Engleman Laboratory at Stanford University. We have assembled a highly qualified management team with broad experience in myeloid biology and drug development to execute our mission. Our scientific founders and management team collectively have extensive experience in immunology, oncology drug development, and patient care. We are industry veterans with prior experience at companies such as Astellas, Immunomedics, Jazz, Maxygen, Seagen, Roche / Genentech, and others. 

Strategy 

Our goal is to become a leading immuno-oncology company, leveraging our myeloid biology expertise and proprietary Boltbody ISAC approach to discover, develop, and commercialize transformative treatments to address key unmet medical needs in cancer. The key components of our strategy are to: 

•Leverage our Boltbody ISAC approach and myeloid expertise to develop our pipeline of immune-activating therapies. Our expertise in myeloid biology and immuno-oncology has led us to research various tumor antigens across solid tumors where significant unmet medical needs remain. Our expertise in medicinal chemistry and antibody engineering and our ability to modulate TLR-agonist linker-payloads allow us to optimize the therapeutic profile of our product candidates for any target tumor antigens as part of our research and development efforts to produce durable anti-tumor responses. We believe that our approach is applicable 

4

Table of Contents

to a broad spectrum of tumor-associated antigens expressed on cancers, including cancers that are refractory to existing therapies. 

•Develop BDC-3042, our agonist antibody targeting dectin-2. dectin-2 represents an attractive target found in a broad range of solid tumors. BDC-3042 targets macrophages in the tumor microenvironment to initiate robust innate and adaptive immune responses. We believe that this differentiated approach could improve the lives of patients by producing durable anti-tumor responses. In October 2023, we dosed the first patient with BDC-3042 in the Phase 1 dose-escalation study in patients with a broad range of solid tumors and we expect to announce results in the second quarter of 2025.

•Develop